Second Study links Phospha E to healthy cardiovascular function 

The study data showed that this unique form of vitamin E lowered bad cholesterol concentrations in blood by up to 44% and triglycerides by up to 51% in mice fed normal diets. When fed high cholesterol diets, Phospha E significantly reduced plaque formation in the aorta by 58%. In contrast, regular vitamin E had no significant effect on plaque formation, or cholesterol levels. These results confirm the earlier animal study indicating that Phospha E may have the potential to yield healthier levels of total cholesterol, triglycerides and LDL-C in humans. The animal model chosen for the trials is commonly used in cardiovascular research as it mimics many of the properties observed clinically in humans.

"We are encouraged that these results support the earlier animal study. Based on these animal studies, as well as earlier in vitro studies, we are confident in the potential of Phospha E to support cardiovascular health in humans," said Dr Esra Ogru, Executive Director of Research and Development.

"We are very pleased with these results as we continue to push forward with research into the benefits of Phospha E. Phosphagenics intends to commence clinical trials in humans to provide further support for the product's health benefits, including its effect on cardiovascular health," said Dr Ogru.

Phosphagenics has a licensing agreement with Zila Nutraceuticals, Inc., USA, a wholly owned subsidiary of Zila, Inc., for the production and distribution of its product under the Ester E brand in the United States, Canada and Indonesia. Ester E is currently sold widely in the United States through retail chains and health food stores.

For further information, please contact Dr Esra Ogru, Phosphagenics Limited on +61 3 9605 5900 or 0402 080 846.